Neurosense Therapeutics Ltd (NRSN) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.71x
Neurosense Therapeutics Ltd (NRSN) has a Cash Flow-to-Debt Ratio of -0.71x as of December 2025, meaning its operating cash flow of $-1.84 Million could theoretically repay -1% of its total liabilities ($2.59 Million) in one year. See financial agility of Neurosense Therapeutics Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.71x
Operating CF / Total Liabilities
Operating Cash Flow
$-1.84 Million
USD
Total Liabilities
$2.59 Million
USD
Data as of
Dec 2025
Most recent filing
Neurosense Therapeutics Ltd Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Neurosense Therapeutics Ltd across 7 annual periods. For the full cash flow conversion analysis, see NRSN operating cash flow.
Annual Cash Flow-to-Debt Ratio for Neurosense Therapeutics Ltd (2019–2025)
Year-by-year debt coverage analysis for Neurosense Therapeutics Ltd.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.96x | $-7.67 Million | $2.59 Million | ▲ +41.7% |
| 2024 | -5.09x | $-10.13 Million | $1.99 Million | ▼ -201.1% |
| 2023 | -1.69x | $-8.35 Million | $4.94 Million | ▲ +53.4% |
| 2022 | -3.63x | $-7.59 Million | $2.09 Million | ▼ -471.7% |
| 2021 | -0.63x | $-1.54 Million | $2.42 Million | ▲ +89.0% |
| 2020 | -5.79x | $-695.00K | $120.00K | ▲ +63.2% |
| 2019 | -15.73x | $-582.00K | $37.00K | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.